Market capitalization | €5.33b |
Enterprise Value | €6.12b |
P/E (TTM) P/E ratio | 32.58 |
EV/FCF (TTM) EV/FCF | 22.77 |
EV/Sales (TTM) EV/Sales | 5.27 |
P/S ratio (TTM) P/S ratio | 4.59 |
P/B ratio (TTM) P/B ratio | 3.30 |
Dividend yield | 1.15% |
Last dividend (FY23) | €1.15 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a DiaSorin S.p.A. forecast:
15 Analysts have issued a DiaSorin S.p.A. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,161 1,161 |
7%
7%
|
|
Gross Profit | 697 697 |
10%
10%
|
|
EBITDA | 383 383 |
14%
14%
|
EBIT (Operating Income) EBIT | 247 247 |
20%
20%
|
Net Profit | 168 168 |
11%
11%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis & retrovirus, oncology and endocrinology. The company was founded in 1968 and is headquartered in Vercelli, Italy.
Head office | Italy |
CEO | Carlo Rosa |
Employees | 3,233 |
Founded | 1968 |
Website | www.diasorin.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.